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Lymphokines capable of mediating a variety of biological activities are secreted 
by T  cells after exposure to polyclonal T  cell mitogens, such as phytohemagglu- 
tinin (PHA) or concanavalin A (Con A), or after specific antigenic stimulation 
during the development of cell-mediated immunity (reviewed in 1). One of these 
lymphokines, gamma interferon (IFN-~), possesses antiviral activity and is able 
to induce macrophage tumoricidal activity in vitro (2). Still unresolved is whether 
IFN-~,  is  the  only lymphokine capable  of activating macrophages to  destroy 
tumor  cells.  One  approach  for  resolving  this  issue  would  be  to  produce  a 
monoclonal antibody able to neutralize  the activities of IFN-7. Here we report 
the isolation ofa hybridoma that secretes a monoclonal rat IgG1 antibody (MAb) 
which neutralizes both the antiviral activity of murine IFN-~, (MuIFN-'y) and the 
ability of lymphokine preparations to induce macrophage tumoricidai activity. 
Materials and Methods 
Animals.  Male (A × C57BL/6)F~ (AB6FI) mice, 8-12 wk of age, and female DA strain 
rats, 8-10 wk of age, were used throughout the studies. All animals were provided by the 
Trudeau Institute Animal Breeding Facility. 
Production and Partial Purification of MulFN-%  High-titered MuIFN-7 was produced 
by PHA-stimulated spleen  cells  derived  from AB6F~  mice infected  intravenously  6  d 
earlier with a sublethal dose of 2 ×  10 s Listeria monocytogenes (3). From the unfractionated 
spleen cell supernatant,  MuIFN-7 was partially purified 50-fold to a specific activity (sp 
act) of 5  x  105  U/mg protein by Con A  affinity chromatography (4,  5).  This partially 
purified MuIFN-~ was used for the immunization of rats. 
Immunization of Rats, Cell Fusion Procedure, and Cloning of Hybridomas.  Rats of the DA 
strain were injected each time subcutaneously with 32,000 antiviral units of the partially 
purified MuIFN-'y emulsified in Freund's adjuvant. The schedule of injections, timing of 
bleedings, and  specificity of antisera  were detailed  previously (5).  19  wk after the  last 
injection, one rat was injected intravenously with 32,000 U of MuIFN-7.4 d later, spleen 
cells from the rat were mixed at a 5:1  ratio with cells of the mouse P3U-1  myeloma line 
and hybridomas were allowed to form in the presence of polyethylene glycol 1450 (J. T. 
Baker Chemical Co., Phillipsburg, N  J) using standard procedures (6). Cells were suspended 
in Dulbecco's modified Eagle's medium (DME)supplemented with 10% fetal bovine serum 
(FBS)  and  seeded  into  16-mm  diam  wells.  The  following  day,  all  wells  received  an 
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additional  equal  volume  of medium  containing  2×  hypoxanthine,  aminopterin,  and 
thymidine (HAT).  1 wk later,  this medium was removed and the cultures  replenished 
with medium containing only hypoxanthine and thymidine. After 7-10 d, the hybridoma 
supernatants were screened for antibodies capable of neutralizing the antiviral activity of 
MuIFN-3,. 
1 well out of 240 was positive for neutralization activity and hybridomas were expanded 
and screened again for anti-MuIFN-3, activity. Positive hybridomas were subcloned twice 
by limiting dilution in microtiter plates with irradiated thymocyte feeder layers in DME 
containing 20%  FBS (7).  The cloned hybridoma (R4-6A2) was expanded and the Ig in 
the culture supernatant was precipitated by 45% saturation with (NH4)eSO4.  The precip- 
itate was resuspended in phosphate-buffered saline (PBS), pH 7.4, to 1/30 of the original 
volume, dialyzed exhaustively in PBS, and then sterile filtered. 
IFN and Antibody Neutralization  Assays.  IFN  assays  were  carried  out  as  previously 
described (8) using L929B cells and vesicular stomatitis virus (VSV) as the challenge virus. 
Since  no  MuIFN-3,  international  standard  is available, included  in  each assay was the 
MuIFN international standard G-002-904-511. 
The antiviral activity neutralization  assay for the detection and quantitation  of anti- 
MuIFN-3, activity in hybridoma supernatants was performed as described (5). In brief, an 
equal  volume  (0.05  ml)  of hybridoma  culture  supernatant  and  the  partially  purified 
MuIFN-~ (final concentration  10 U/ml) were mixed together in 96-well microtiter plates 
and incubated at 37°C for 1 h. After this time, 0.1  ml of L929B cells (1.8 ×  10~/ml) were 
added to each well and incubated for 18 h.  Each of the wells was then challenged with 
VSV at a multiplicity of infection of 0.1  and examined at 48 h  for neutralization of the 
antiviral activity of the test MuIFN-3,. 
Macrophage Tumoricidal Assay.  The ability of lymphokine preparations to induce mac- 
rophage tumoricidal activity in vitro was assayed by established procedures (9).  Macro- 
phage-rich exudates were harvested from the peritoneal cavities of AB6F~  mice injected 
3 d earlier with 1.0 ml of a  10% solution of proteose-peptone. The cells were washed and 
resuspended  at  106  cells/ml  in  RPMI  1640  (Gibco  Laboratories,  Grand  Island,  NY) 
supplemented with sodium pyruvate and 5% FBS (Sterile Systems, Logan, UT). 0.2 ml of 
cells were allowed to adhere to the wells of a  rnicrotiter plate (Costar, Data Packaging, 
Cambridge,  MA).  2  h  later,  nonadherent  cells  were  washed  off and  0.2  ml  of test 
lymphokine preparations were added to groups of triplicate wells. Control macrophages 
without lymphokines were included  in every experiment as a  measure of spontaneous 
cytotoxicity and this activity was subtracted as background (spontaneous release) from the 
data. To each of the wells,  10 ng of endotoxin (Escherichia coli 0111 :B4; Sigma Chemical 
Co., St.  Louis, MO) was also added. Each of the lymphokine preparations was incubated 
for 1 h at 37 °C with different concentrations of the MAb against MuIFN-3,, before the 
addition  to the  macrophages.  5  h  later, after the addition  of lymphokines, 0.01  ml of 
P815 mastocytoma cells (provided by Dr. R. Schreiber), which had been labeled with 5~Cr 
(50-400  mCi/mg;  Amersham  Corp.,  Arlington  Heights,  IL)  according  to  published 
methods (9), was added directly to each of the wells at an effector to target ratio of 5:1. 
Sixteen  hours  later,  the  uppermost 0.1  ml of fluid  from each well  was collected and 
counted in an LKB Rack Gamma II gamma counter (LKB Instruments, Inc., Gaithersburg, 
MD). Tumoricidal activity was assessed by the following formula: Percent specific 5~Cr 
release  --  [(experimental  release  -  spontaneous  release)](total  release  -  spontaneous 
release)] ×  100. 
lmmunoadsorption of Lymphokine Preparations.  The concentrated  MAb culture  super- 
natant was coupled to CNBr-activated Sepharose 4B beads according to manufacturer's 
instructions (Pharmacia, Inc., Piscataway, N  J). Mock Sepharose beads were generated by 
treating CNBr-activated Sepharose 4B, in the absence of protein, under identical condi- 
tions.  Lymphokines were diluted to 128  IFN U/ml, mixed either with MAb coupled to 
Sepharose beads or mock Sepharose beads, and rotated for 15 h  at room temperature. 
The beads were then pelleted at 200 g for 5 rain and the supernatant tested for antiviral 
and tumoricidal inducing activities. 
Biological Reagents.  The isotype of the MAb was determined by double diffusion in 
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TABLE  I 
Spec~city of Rat Monoclonal Anti-MulFN-'y 
Production mode 
Interferon  Fraction 
System  Induction 
Neutralization 
titer* for anti- 
viral activity 
MulFN-~  Spleen cells  Con A*  --  14,000 
MulFN-~,  Spleen cells  PHA  !  --  13,000 
MulFN-7  Spleen cells  PHA  !  Con A-bound  I  13,000 
MulFN-7  Spleen cells  PHA I  Con A-unbound  I  13,000 
MuIFN-7  Recombinant DNA  I  --  --  13,000 
MuIFN-  7  Serum  BCG/OT**  --  13,000 
MuIFN-7  MLR  Allogeneic cells  *r  --  26,000 
MuIFN a  + 13  N  C-243  Virus  --  <20 
Rat IFN-3,  Spleen cells  PHA  !1  --  <20 
Human IFN-1,  Blood leukocytes  PHA  ~  --  <20 
* Neutralization  titer is defined as the reciprocal of the highest dilution of antibody that, when mixed with an 
equal volume of IFN-~ (final IFN-~ concentration,  10 U/ml), neutralizes 50% of the antiviral activity as judged 
by the development of viral cytopathic effect (5). 
* Spleen cells from Listeria-immune AB6FI mice were stimulated in vitro with 2 #g/ml Con A as described. 
e Same as in *, except spleen cells were stimulated with 5 ug/ml PHA. 
I A PHA-induced MuIFN-~' was fractionated by Con A affinity chromatography into Con A-bound and Con A- 
unbound fractions (4, 5). 
I Highly purified  IFN-7 (>10  T U/rag) produced  by cloned  MuIFN-~, genes transfected  to E.  coli and  kindly 
supplied by Genentech, Inc. 
** (A × C57BL/6)FI mice were injected with 5 x  10  ~ Mycobacterium  bovis (BCG) and 21  d later inoculated with old 
tuberculin (OT) (10 mg total protein). Serum was collected 2 h after injection of old tuberculin. 
Mixed lymphocyte reaction (MLR)-induced IFN-~ was produced as described previously (5). 
u Pure IFN a  +/3 were purchased from Enzo Biochem Inc., New York. 
tl Spleen cells from DA rats injected 6 d earlier with 5 x  l& Listeria  monocytogenes subcutaneously were suspended 
at l0 T  cells/ml in RPMI 1640 with 10 tag/ml gentamycin and stimulated with 5 #g/ml PHA for 24 h. 
Human IFN-~, induced by PHA induction of blood leukocytes and generously supplied by Flow Laboratories, 
Inc. 
IL. By this procedure the MAb was determined to be in the IgG1 subclass. With a radial 
immunodiffusion kit (Miles Laboratories, Inc.), the concentration of MAb protein in the 
concentrated culture supernatant was determined to be 1.55 mg/ml. To neutralize the 
antiviral activity of 10 U of MuIFN-% 30.0 ng of MAb was required. 
A variety of mouse, rat, and human IFN were included in studies to test the specificity 
of the MAb. The source and mode of production for each of these IFN are included in 
the footnotes to Table I. 
Results and Discussion 
The specificity of the neutralizing activity of the concentrated MAb, R4-6A2, 
was tested against  a  variety of MuIFN-7  preparations.  The  results  in  Table  I 
show that regardless of the source of MuIFN-y, the antiviral activity of each of 
the samples was neutralized  to an approximately similar degree as the original 
immunogen.  It  was  also  determined  that  the  MAb  neutralized  equally  the 
antiviral activity of both the native 41,000 tool wt form (3) and the 20,500 tool 
wt species generated  under  denaturing  conditions  (10) (results not shown).  In 
contrast, the antivirai activity of MuIFN-a plus MuIFN-13, human IFN-% and rat 
IFN-7 was not neutralized  by the MAb. Our finding that the antiviral activities 
of glycosylated and nonglycosylated (recombinant MuIFN-~, produced by E. coli) 
MuIFN-7 were neutralized equally indicates that the epitope recognized by the 
MAb is a constituent of the polypeptide structure of the MuIFN-7 molecule. 
Experiments  next investigated whether the MAb could neutralize  the ability 
of lymphokine preparations to induce macrophage tumoricidal activity in vitro. 
The amount of MuIFN-'y used for activation of macrophages was based on the 
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TABLE  II 
Inhibition of Lymphokine-induced Macrophage Tumoricidal Activity by MAb to MulFN-7 
IFN preparation 
Percent specific StCr release* 
Plus excess  Relative excess of MAb}  No  MAb 
MAb 
No MAb  2x  5x  10x  2x  5× 
IFN titer* 
U/ml 
Con A-induced MulFN-~  i  30,8 3= 1.4  21.4 3= 3.4  14.2 3= 0.5  10.5 3= 1.2  8  <4  <4 
PHA-induced MulFN-71  31.3 3= 1.4  23.0 ±  1.4  13.8 ±  1.0  1 I.I ±  2.3  8  <4  <4 
PHA-induced MuIFN-~  i (Con  29,1 ±  3.3  17.5 3= 2.9  11.3 3= 2.3  10.5 ±  1.7  16  <4  <4 
A-bound fraction) 
PHA-induced MuIFN-~  ,i (Con  33.4 ±  2.8  26.7 ±  1.2  20.0 ±  3.2  13,6 :t: 3.1  8  <4  <4 
A-unbound fraction) 
Recombinant DNA MulFN-~  ,°  32.6 ±  2.0  23.8 ±  1.8  14.7 ±  2,1  10.6 =l= 1.7  16  <4  <4 
MuIFN-a +  MuIFN-~  6.3 ±  1.2  4.0 ±  2.0  --  --  128  128 
Con A-induced MuIFN--y**  32,6 ±  1.7  --  --  35.3 =l= 2.7  --  --  -- 
* Total cell-associated S~Cr determined by lysing P815 target cells with Triton X-100. Mean of triplicate samples 
for three separate experiments :1= SEM. 
* The IFN titer is defined as the reciprocal of the highest dilution of the sample that protects 50% of the assay 
cells (L929 B) from viral (vesicular stomatitis virus) cytopathic effect, 
! The quantity of MAb reacted was based on neutralization of the antiviral activity of each preparation. Since the 
antibody titer was determined by the inhibition of 50% of the activity (see legend to Table I), it was necessary 
to add at least twofold more antibody to abolish all antiviral activity. 
! Lymphokines prepared according to methods outlined in legend to Table I. 
I Pure IFN a  +/3 were produced by Newcastle disease virus-induced mouse C-243 cells. 
** Macrophages were incubated with lymphokines for 5 h before the addition of MAb. 
maximum expression of tumoricidal activity. Each sample tested for its ability to 
activate macrophages was simultaneously assayed for antiviral activity. In addi- 
tion,  individual control wells consisting of macrophages or 5~Cr-labeled tumor 
cells were incubated with each of the concentrations of lymphokines, antibody, 
or combinations of both, and these were consistently found not to be toxic to 
the cells as determined by either trypan blue dye exclusion or measurement of 
5~Cr release. The results presented in Table II show that unfractionated lympho- 
kines (sp act,  104  U/mg) and partially pure (Con A bound: sp act, 5  X  10 ~ U/ 
rag) and highly purified (recombinant: sp act, 107 U/rag) MuIFN-3, preparations 
all  induced  macrophages  to  become  tumoricidal.  In  contrast,  a  preparation 
consisting of a mixture of MuIFN-a plus MuIFN-B failed to induce tumoricidal 
activity,  even  when  present  at  10  times  the  quantity  of antiviral  activity  of 
MuIFN-3,.  When test lymphokines were preincubated for  1  h  with  twice the 
amount of MAb required to neutralize 50% of the stated MuIFN-3, concentration 
before the addition to macrophages, antiviral activity was completely abolished 
while tumoricidal activity was  inhibited  25-40%.  To  reduce the tumoricidal- 
inducing  activity  of all  lymphokines  to  <50%  of maximum  activity,  it  was 
necessary to add 5-10-fold more of the MAb than required for the abolishment 
of antiviral activity. With 50-100-fold excess, antibody tumoricidal activity was 
inhibited by 75-90%  (not shown). The addition of MAb to macrophages after 
an  initial  5  h  period of exposure to  lymphokines did not  inhibit  tumoricidal 
activity.  The  reason  that  more  MAb  was  required  to  neutralize  tumoricidal 
activity than  antiviral  activity is  unknown but  may be  related to  the  greater 
sensitivity of the tumoricidal assay. 
Immunoadsorption was also used to  demonstrate that  MuIFN-7  present  in 
lymphokine preparations  was  the  active  mediator  required  for  induction  of 
macrophage  tumoricidal  activity.  The  MAb  was  coupled  to  CNBr-activated 1564  SPITALNY  AND  HAVELL  BRIEF  DEFINITIVE  REPORT 
TABLE  III 
Specific Binding of Lymphokine-induced Antiviral and Macrophage Tumoricidal Activities to 
Immobilized Anti-IFN-'y MAb 
MulFN-,y preparation* 
Activities  of lymphokines before and after incubation with 
MAb coupled to Sepharose beads* 
Antiviral (IFN titer)  Tumoricidal 
(Percent specific SlCr release) 
Before  After  Before  After 
Con A-induced  128  <4  34.6 4- 1.8  1.3 4- 1.1 
PHA-induced  128  <4  34.4 4- 2.0  1.5 4- 2.3 
PHA-induced (Con A-bound  128  <4  33.8 4- 1.5  0.7 4- 1.3 
fraction) 
PHA-induced (Con A-unbound  128  <4  34.4 4- 2.0  1.5 4- 0.7 
fraction) 
Recombinant DNA  128  <4  35.0 4- 2.1  4.9 4- 3.1 
Mock Sepharose beads without coupled MAb* 
PHA-induced  128  128  33.2 4- 1.5  34.1  + 2.2 
Recombinant DNA  128  96  32.9 4- 4.4  31.6 +  3.4 
* Lymphokines were diluted to  128  IFN  U/ml, mixed either with MAb coupled to Sepharose beads or mock 
Sepharose beads and processed as described in Materials and Methods. 
* Lympbokines  prepared according to methods outlined in legend to Table I. 
Sepharose 4B beads, which were then incubated with each of the lymphokine 
preparations. It was found that this procedure removed all of the antiviral activity 
and macrophage tumoricidal activity from each of the lymphokine preparations 
(Table III). Sepharose beads made without MAb failed to remove the antiviral 
and tumoricidal-inducing properties of lymphokines. 
These studies demonstrate that a rat MAb against MuIFN--r, initially screened 
for neutralization of antivirai activity, can also neutralize the ability of lympho- 
kine preparations to activate macrophage tumoricidal activity in vitro. However, 
to achieve this effect, relatively more MAb was required than was needed to 
neutralize antiviral activity. Similar results were obtained whether unfractionated 
lymphokines or partially or highly purified MuIFN-y preparations were used. In 
addition,  published  studies  (i1,  12)  have shown that  an  MAb against  human 
IFN--r was capable of completely inhibiting not only antiviral activity but also 
the  ability  of these  preparations  to  activate  the  secretory and  microbicidal 
functions of peripheral blood monocytes. The results of the combined studies 
with MAb to mouse and human IFN--r, plus our findings that immobilized MAb 
specifically removed all soluble factors capable of activating macrophage tumor- 
icidal  activity  from  lymphokine preparations,  indicates  that  the  induction  of 
macrophage activation and the expression of antiviral activity are mediated by 
the same molecule or by molecules sharing similar epitopes. 
Summary 
Fusion of rat immune spleen cells with mouse myeloma cells resulted in the 
formation  of a  stable  hybridoma  that  secretes  monoclonal  antibody  (MAb) 
directed against  murine gamma interferon (MuIFN-y). This  MAb specifically 
neutralized the antiviral activity of a variety of MuIFN-3, preparations, including 
a sample produced by recombinant DNA technologies. In contrast, the antiviral 
activities of a  mixture of MuIFN-a plus  MuIFN-¢3,  as well as those of rat  or 
human IFN-% were not neutralized by this antibody. The ability of the MAb to SPITALNY  AND  HAVELL  BRIEF  DEFINITIVE  REPORT  1565 
inhibit lymphokine-induced macrophage activation was also tested. It was found 
that  in  relation  to  the  quantity of antibody  needed  to  cotnpletely  neutralize 
antiviral activity, much higher concentrations of MAb were required to abolish 
the  capacity  of  lymphokine  preparations  to  induce  macrophage  tumoricidal 
activity in  vitro.  The  MAb  was  also  coupled  to  cyanogen bromide-activated 
Sepharose  beads  and  used  as  an  immunoadsorbent.  By reacting  lymphokines 
with  MAb  coupled  to  an  insoluble  matrix,  it  was  possible  to  show  that  this 
immobilized antibody completely and specifically removed from the lymphokine 
preparations the ability both to invoke macrophage tumoricidal activity and to 
mediate antiviral activity. 
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